CDX1和CDX2是同源盒型转录因子，是潜在的生物标志物，在淋巴结转移与更好的预后相关之前，与肠型胃癌早期疾病的预后意义相关。此外，先前已知与脑癌有关的基因 IDH 1 和 IDH 2 与癌症相关的分子特征有关，因此新的靶向个性化疗法可能成为可能。我们的回顾性研究确定了 CDX 标记物与临床病理数据（包括胃癌患者的生存率）之间的相关性。这项研究包括 1997 年至 2022 年 12 月的研究，并进行荟萃分析，以提供比值比 (OR) 和相对风险 (RR)。我们详细讨论了 IDH 1/2 对胃癌预后的影响和潜在的治疗策略。我们的荟萃分析包括 20 项研究，涉及 11,163 名胃癌患者。我们发现 CDX 1 过表达与更好的总生存率（合并 HR：1.28）相关，CDX 2 表达与更好的 3 年生存率（合并 HR：1.64）和 5 年生存率相关，合并 HR 与两者相关 1 94统计相关性。有证据表明，IDH 1/2 突变和 CDX 1/2 过度表达与代谢异常表观遗传变化密切相关，突变证据表明胃癌新型靶向治疗的潜力。 CDX 1/2 过度表达与胃癌病例的良好预后相关。需要进一步研究来探索 IDH 1/2 突变和 CDX 1/2 表达的临床意义。© 作者。

CDX1 and CDX2 are homeobox-type transcription factors that are potential biomarkers and are associated with prognostic significance in intestinal-type gastric cancer early disease before lymph node metastasis is associated with better prognosis. In addition, the genes IDH 1 and IDH 2 previously known to be involved in brain cancer are implicated in cancer-related molecular signatures as a result new targeted personalized therapies may be possible. Our retrospective study determined the correlation between CDX markers and clinicopathologic data including survival in patients with gastric cancer. This study included studies from 1997 to December 2022 a meta-analysis to provide odds ratios (ORs) and relative risks (RRs). We discussed in detail the impact of IDH 1/2 on the prognosis of gastric cancer outcomes and potential therapeutic strategies. Our meta-analysis included 20 studies identifying 11,163 patients with gastric cancer. We found that CDX 1 overexpression was associated with better overall survival (pooled HR: 1.28) and CDX 2 expression and better 3-year survival (pooled HR: 1.64) and 5-year survival was the pooled HR was correlated 1 94 with both showing statistical correlation. Evidence suggests that IDH 1/2 mutations and CDX 1/2 overexpression are closely associated with metabolic abnormalities epigenetic changes and mutations evidence suggests the potential for novel targeted therapies in gastric cancer. CDX 1/2 overexpression is associated with a favorable prognosis in gastric cancer cases. Further studies are needed to explore the clinical significance of IDH 1/2 mutations and CDX 1/2 expression.© The Author(s).